Stay on top of the latest research and practice
Symposium Organized by: AstraZeneca
CHAIR: Andreas Du Bois, Germany
12:30 Welcome and Introductions Andreas du Bois, Germany
12:35 Exploring the Rationale for Earlier Intervention with PARP Inhibitors Charles Gourley, United Kingdom
12:55 PARP Inhibitors in the First-line Setting: A Review of the Evidence Sandro Pignata, Italy Isabelle Ray-Coquard, France
13:35 Interpretation, Panel Discussion and Audience Q&A Andreas du Bois, Germany
Symposium Organized by: Ethicon
Moderators: Vito Chiantera, Italy and Santiago Domingo, Spain Chair: Philippe Morice, France
12:30 The Pelvic exenteration in the aortic node positive patients Gwenael Ferron, France
12:45 Surgery or Radiotherapy in the treatment of Pelvic sidewall relapse Vito Chiantera, Italy
13:00 Reconstruction after Pelvic Exenteration: Just Standard or More Complex Reconstruction? Luis M. Chiva, Spain
13:10 Reconstruction after Pelvic Exenteration: Just Standard or More Complex Reconstruction? Jalid Sehouli, Germany
13:20 Debate
13:30 Ovarian cancer relapse after PARP therapy, Surgery or Chemotherapy Anna Fagotti, Italy
13:40 Ovarian cancer relapse after PARP therapy, Surgery or Chemotherapy Barbara Schmalfeldt, Germany
13:50 Debate
Symposium Organized by: Medtronic
Chair: Frédéric Kridelka, Belgium
15:30 Introduction by Chairman Frédéric Kridelka, Belgium
15:35 LACC Trial – Interpreting of the Trial Results and Implications on Future Clinical Trial Design Andreas Obermair, Austria
15:50 Developments in ICG Technology in Targeting Sentinel Node Biopsy Karl Tamussino, Austria
16:05 Is the Future of Surgery in Genycological Cancer Bright or Gloomy? Frédéric Kridelka, Belgium
16:20 Questions and Answers All faculty
Symposium Organized by: TESARO a GSK Company
15:30 Introduction Andreas du Bois, Germany
15:35 Latest data on PARPi maintenance in first-line ovarian cancer Antonio González-Martin, Spain
15:50 How to treat newly diagnosed ovarian cancer patients: considering all the options Andreas du Bois, Germany
16:05 Efficacy of anti-PD-1 in endometrial cancer: what's the news? Ana Oaknin, Spain
16:20 Conclusion Nicoletta Colombo, Italy
Symposium Organized by: Genmab and Seattle Genetics
CHAIR: Mansoor Raza Mirza, Denmark
The symposium session will be primarily discussion based, focusing on the opinions and insights of the expert panel as well as audience input and feedback. Some slides will be used to set the scene and guide the discussions, but the symposium does not fit into the standard presentation/discussion format.
Introduction Mansoor Mirza, Denmark
Current Treatment Landscape for Recurrent/Metastatic Cervical Cancer Mansoor Mirza, Denmark
Surgical Intervention in Recurrent Cervical Cancer David Cibula, Czech Republic
Patient Perspectives on Treatment David Cibula, Czech Republic
New Treatments in Development for Recurrent/Metastatic Cervical Cancer: Immuno-Oncology Mansoor Mirza, Denmark
New Treatments in Development for Recurrent/Metastatic Cervical Cancer: Antibody Drug Conjugates Ana Oaknin, Spain
Panel Q&A
Symposium Organized by: Clovis Oncology, Inc.
CHAIR: Domenica Lorusso, Italy
13:00 Welcome and Introduction Domenica Lorusso, Italy
13:05 All Eyes on PARPi: Advances in Maintenance Therapy for Recurrent Ovarian Cancer Andreas du Bois, Germany
13:25 Case Studies: Informed Decision Making for the Treatment of Patients with Recurrent Ovarian Cancer Domenica Lorusso, Italy
13:45 Is Active Surveillance Active Enough for Patients with Recurrent Ovarian Cancer? Panel
14:05 Looking to the Future of PARP Inhibitors in Ovarian Cancer Treatment Eric Pujade-Lauraine, France
14:20 Panel Q&A and Close Domenica Lorusso, Italy
Symposium Organized by: Intuitive Surgical
CHAIR: Pedro Ramirez, USA
16:00 The place of da Vinci robotic-assisted surgery in an Enhanced Recovery Program Eric Lambaudie, France
16:30 Early recovery after da Vinci robotic-assistedb post operative results Celine Lönnefors, Sweden
Symposium Organized by: PharmaMar
CHAIR: Sandro Pignata, Italy
16.00 Introduction: What has changed? Sandro Pignata, Italy
16.15 When platinum re-challenge might be justified Domenica Lorusso, Italy
16.30 What if the symptomatic response is a priority? Antonio González, Spain
16.45 Facing an early symptomatic relapse Isabelle Ray-Coquard, France
Not yet an ESGO member?
Join or renew today
› ESGO's successful Textbook is back!
Special Platinum Release only at ESGO 2023, Pre-order Now!
*Limited Copies
Get notified on all news and activities right in your mailbox.
Find out More
Scientific Programme Highlights
Explore it Now!
Great moments from ESGO 2022!
View it Now!
Regular rates end on Sept 10!
Register Now!